« Run It Past the Chemists |
| Lilly's R&D Outsourcing »
January 5, 2010
Always Read the Fine Print
. . .especially when you're dealing with the Swiss. You'll have probably seen that Novartis is buying Alcon. But what price they're buying them at depends on who you are.
As the Wall Street Journal reports, Novartis, who already had 25% of Alcon's stock, is paying majority shareholder Nestlé $180/share for their 52% stake in the company. Minority shareholders - that is, all the rest of them - are being offered $153. Some of these folks have paid up over $160/share recently, anticipating such a deal, but under Swiss law, there's not a thing that they can do about it. . .
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- Some New Reviews
- A Structure From the Molecular Sponge
- Biggest US Cities for Biopharma Funding, Versus Whole Continents.
- We Are Pleased To Publish Your Senseless Ravings
- Traveling Interruption
- More Good PD-1 News in Cancer
- Novartis's Stealthy Headcount Reductions
- Sydney Brenner on the State of Science